CN117279933A - 相对于hras和nras具有选择性kras抑制作用的环状化合物 - Google Patents

相对于hras和nras具有选择性kras抑制作用的环状化合物 Download PDF

Info

Publication number
CN117279933A
CN117279933A CN202280032929.5A CN202280032929A CN117279933A CN 117279933 A CN117279933 A CN 117279933A CN 202280032929 A CN202280032929 A CN 202280032929A CN 117279933 A CN117279933 A CN 117279933A
Authority
CN
China
Prior art keywords
alkyl
group
hydrogen
membered
groups
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280032929.5A
Other languages
English (en)
Chinese (zh)
Inventor
河田发夫
鹰野宏治
小竹智也
阴未来
桥本哲
田宫实
若宫佑真
林龙儿
森田雄也
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chugai Pharmaceutical Co Ltd
Original Assignee
Chugai Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd
Publication of CN117279933A publication Critical patent/CN117279933A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202280032929.5A 2021-05-07 2022-05-06 相对于hras和nras具有选择性kras抑制作用的环状化合物 Pending CN117279933A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2021-079012 2021-05-07
JP2021079012 2021-05-07
PCT/JP2022/019544 WO2022234853A1 (ja) 2021-05-07 2022-05-06 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物

Publications (1)

Publication Number Publication Date
CN117279933A true CN117279933A (zh) 2023-12-22

Family

ID=83932768

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280032929.5A Pending CN117279933A (zh) 2021-05-07 2022-05-06 相对于hras和nras具有选择性kras抑制作用的环状化合物

Country Status (17)

Country Link
US (1) US20240158446A1 (https=)
EP (1) EP4309741A4 (https=)
JP (1) JPWO2022234853A1 (https=)
KR (1) KR20240005777A (https=)
CN (1) CN117279933A (https=)
AR (1) AR125796A1 (https=)
AU (1) AU2022268781A1 (https=)
BR (1) BR112023022755A2 (https=)
CA (1) CA3218182A1 (https=)
CL (1) CL2023003137A1 (https=)
CO (1) CO2023014807A2 (https=)
CR (1) CR20230572A (https=)
IL (1) IL307605A (https=)
MX (1) MX2023013139A (https=)
PE (1) PE20250071A1 (https=)
TW (1) TW202309063A (https=)
WO (1) WO2022234853A1 (https=)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385867A (zh) * 2022-09-19 2022-11-25 安徽普利药业有限公司 一种氨基酸及其类似物的成环反应与开环方法

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202446781A (zh) 2011-12-28 2024-12-01 日商中外製藥股份有限公司 胜肽化合物之製造方法
EP4166664A1 (en) 2015-03-13 2023-04-19 Chugai Seiyaku Kabushiki Kaisha Modified aminoacyl-trna synthetase and use thereof
JP7187323B2 (ja) 2017-01-31 2022-12-12 中外製薬株式会社 無細胞翻訳系におけるペプチドの合成方法
KR20250007021A (ko) 2017-06-09 2025-01-13 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
EP3878836B1 (en) 2018-11-07 2025-07-23 Chugai Seiyaku Kabushiki Kaisha O-substituted serine derivative production method
EP4056580A4 (en) 2019-11-07 2023-12-06 Chugai Seiyaku Kabushiki Kaisha METHOD FOR PRODUCING A PEPTIDE COMPOUND COMPRISING A STERICALLY HINDERED AMINO ACID
BR112022007535A2 (pt) 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras
US12312379B2 (en) 2021-05-07 2025-05-27 Chugai Seiyaku Kabushiki Kaisha Methods for producing cyclic compounds comprising N-substituted amino acid residues
JP7823181B2 (ja) * 2022-05-06 2026-03-03 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
TW202430537A (zh) * 2022-10-20 2024-08-01 日商中外製藥股份有限公司 環狀胜肽的結晶的製造方法
EP4603105A1 (en) * 2022-11-09 2025-08-20 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras
CN120659773A (zh) * 2022-11-09 2025-09-16 锐新医药公司 化合物、复合物以及其制备方法和用途
WO2024101386A1 (ja) * 2022-11-09 2024-05-16 中外製薬株式会社 Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
WO2024195801A1 (ja) 2023-03-20 2024-09-26 中外製薬株式会社 環状ペプチドの共結晶の製造方法
TW202506168A (zh) 2023-04-19 2025-02-16 日商中外製藥股份有限公司 包含環狀胜肽化合物及界面活性劑之組合物
CN120936619A (zh) 2023-04-20 2025-11-11 中外制药株式会社 用于生产环肽化合物的方法
CN116655766B (zh) * 2023-04-23 2023-12-12 山东第一医科大学(山东省医学科学院) 一种订书肽及其制备方法和应用
US20250049810A1 (en) 2023-08-07 2025-02-13 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025162428A1 (en) * 2024-01-29 2025-08-07 Syneron Technology Co. Ltd. Cyclic peptide compounds and compositions as ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
CN118324664B (zh) * 2024-03-14 2026-04-07 四川鸿日医药科技有限公司 一种丝氨酸衍生物的制备方法
TW202547461A (zh) 2024-05-17 2025-12-16 美商銳新醫藥公司 Ｒａｓ抑制劑
WO2025255438A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026004834A1 (ja) * 2024-06-25 2026-01-02 中外製薬株式会社 固体分散体、及びそれを含む組成物
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026009920A1 (ja) * 2024-07-03 2026-01-08 中外製薬株式会社 環状ペプチドの精製法及び製造法
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2586411T3 (es) 2011-03-04 2016-10-14 New York University Macrociclos sustitutos de enlace de hidrógeno como moduladores de Ras
TW202446781A (zh) 2011-12-28 2024-12-01 日商中外製藥股份有限公司 胜肽化合物之製造方法
WO2015179438A1 (en) * 2014-05-20 2015-11-26 Ohio State Innovation Foundation Small molecule rac or rho inhibitors
US10954287B2 (en) * 2016-04-15 2021-03-23 Ra Pharmaceuticals, Inc. Ras binding peptides and methods of use
CN110869544B (zh) 2017-06-09 2024-03-08 中外制药株式会社 膜透过性高的环状肽化合物及包含其的文库
KR20250007021A (ko) * 2017-06-09 2025-01-13 추가이 세이야쿠 가부시키가이샤 N-치환 아미노산을 포함하는 펩타이드의 합성 방법
WO2020122182A1 (ja) * 2018-12-12 2020-06-18 中外製薬株式会社 分子内水素結合可能な官能基を有するアミノ酸とそれらのアミノ酸を含むペプチド化合物、およびそれらの製造方法
BR112022007535A2 (pt) * 2019-11-07 2022-07-12 Chugai Pharmaceutical Co Ltd Composto peptídico cíclico tendo ação inibitória de kras

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN115385867A (zh) * 2022-09-19 2022-11-25 安徽普利药业有限公司 一种氨基酸及其类似物的成环反应与开环方法

Also Published As

Publication number Publication date
CL2023003137A1 (es) 2024-06-14
IL307605A (en) 2023-12-01
PE20250071A1 (es) 2025-01-13
CR20230572A (es) 2024-01-25
CA3218182A1 (en) 2022-11-10
MX2023013139A (es) 2023-11-28
AR125796A1 (es) 2023-08-16
TW202309063A (zh) 2023-03-01
JPWO2022234853A1 (https=) 2022-11-10
US20240158446A1 (en) 2024-05-16
EP4309741A1 (en) 2024-01-24
WO2022234853A1 (ja) 2022-11-10
KR20240005777A (ko) 2024-01-12
EP4309741A4 (en) 2025-05-14
BR112023022755A2 (pt) 2024-01-02
CO2023014807A2 (es) 2023-11-20
AU2022268781A1 (en) 2023-12-21

Similar Documents

Publication Publication Date Title
CN117279933A (zh) 相对于hras和nras具有选择性kras抑制作用的环状化合物
JP7823181B2 (ja) Ｈｒａｓおよびｎｒａｓに対して選択的なｋｒａｓ阻害作用を有する環状化合物
EP4603105A1 (en) Pharmaceutical composition containing cyclic compound having selective kras inhibitory effect against hras and nras
EP4592308A1 (en) Cyclic compound having selective kras inhibitory effect on hras and nras
US12371454B2 (en) Cyclic peptide compound having Kras inhibitory action
JP7179241B1 (ja) 環状ペプチド化合物の医薬用途
WO2022234639A1 (ja) 変異型ｒａｓ（ｇ１２ｄ）に対する選択的結合性を示す結合分子
JP7032808B2 (ja) ペプチドもしくはその薬学的に許容される塩、またはそれらのプロドラッグ
KR20240082196A (ko) Hras 및 nras에 대해서 선택적인 kras 저해 작용을 갖는 환상 화합물을 포함하는 의약 조성물
HK40096863A (zh) 相对於hras和nras具有选择性kras抑制作用的环状化合物
HK40117379A (zh) 相对於hras和nras对kras具有选择性抑制作用的环状化合物
HK40124102A (zh) 包含具有相对於hras和nras的选择性kras抑制作用的环状化合物的药物组合物
HK40096352A (zh) 环状肽化合物的药物用途
HK40066330B (zh) Masp抑制化合物及其用途
HK40066330A (zh) Masp抑制化合物及其用途

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40096863

Country of ref document: HK